CLINICAL STUDIES ON TA-058

Abstract

TA-058, a new parenteral penicillin, has been investigated to give following results.
Eleven patients with various infectious diseases including pneumonia, tonsillitis, acute pyelonephritis and septicaemia were treated with 2-3 g daily dose of TA-058 for 3 to 14 days. It was 63% of the efficacy rate.
Neither adverse effect, nor abnormal laboratory findings were noted except for the elevation of GOT and GPT in only one case with chronic hepatitis.